Back to top
more

Hims & Hers Health (HIMS)

(Delayed Data from NYSE)

$12.29 USD

12.29
6,997,661

-0.63 (-4.88%)

Updated May 10, 2024 04:00 PM ET

After-Market: $12.24 -0.05 (-0.41%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (146 out of 251)

Industry: Medical Info Systems

Better trading starts here.

Zacks News

Moumi Mondal headshot

Here's How Medtronic (MDT) Is Placed Ahead of Q4 Earnings

Medtronic's (MDT) rapid cadence of new product approvals is a strong foundation for future growth. However, the company also navigates some macroeconomic challenges.

Nalak Das headshot

5 Medical Info Systems Stocks to Buy for Stable Returns

We have narrowed our search to five medical info systems stocks that have strong growth potential for 2024. These stocks are: HIMS, BFLY, ENOV, LUNG, DH.

Phibro (PAHC) Q3 Earnings and Revenues Beat, Gross Margin Down

Phibro's (PAHC) impressive fiscal 2024 third-quarter performance continues to be driven by the Animal Health segment.

National Vision (EYE) Q1 Earnings Beat Estimates, Margins Down

National Vision (EYE) delivers improved revenues in the first quarter of 2024 in a challenging macro environment.

Hims & Hers Health (HIMS) Upgraded to Strong Buy: What Does It Mean for the Stock?

Hims & Hers Health (HIMS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Best Momentum Stock to Buy for May 8th

HIMS, CHRW and WRK made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on May 8, 2024.

New Strong Buy Stocks for May 8th

BRFS, GPS, GTN, HIMS and SIGA have been added to the Zacks Rank #1 (Strong Buy) List on May 8, 2024.

Hims & Hers Health, Inc. (HIMS) Q1 Earnings and Revenues Top Estimates

Hims & Hers Health (HIMS) delivered earnings and revenue surprises of 150% and 2.76%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Urmimala Biswas headshot

Should You Buy Hims & Hers Health (HIMS) Ahead of Q1 Earnings?

Hims & Hers Health's (HIMS) first-quarter earnings are expected to have benefited from its strategy of placing its solutions at attractive price points.

Bears are Losing Control Over Hims & Hers Health (HIMS), Here's Why It's a 'Buy' Now

After losing some value lately, a hammer chart pattern has been formed for Hims & Hers Health (HIMS), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

Brokers Suggest Investing in Hims & Hers Health (HIMS): Read This Before Placing a Bet

Based on the average brokerage recommendation (ABR), Hims & Hers Health (HIMS) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?

Is Most-Watched Stock Hims & Hers Health, Inc. (HIMS) Worth Betting on Now?

Hims & Hers Health (HIMS) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

P3 Health Partners Inc. (PIII) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

P3 Health Partners (PIII) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Why Hims & Hers Health, Inc. (HIMS) Outpaced the Stock Market Today

Hims & Hers Health, Inc. (HIMS) concluded the recent trading session at $12.50, signifying a +1.87% move from its prior day's close.

Hims & Hers Health, Inc. (HIMS) Stock Sinks As Market Gains: What You Should Know

Hims & Hers Health, Inc. (HIMS) reachead $11.88 at the closing of the latest trading day, reflecting a -0.17% change compared to its last close.

Zacks Investment Ideas feature highlights: Hims & Hers Health, Coinbase Global

Hims & Hers Health, Coinbase Global have been highlighted in this Investment Ideas article.

Hims & Hers Health, Inc. (HIMS) Suffers a Larger Drop Than the General Market: Key Insights

Hims & Hers Health, Inc. (HIMS) closed the most recent trading day at $12.34, moving -0.56% from the previous trading session.

Ethan Feller headshot

Investing in Growth: 2 Top-Ranked Stocks with Huge Potential

Strong sales growth is a beacon for investors seeking promising companies

Hims & Hers Health, Inc. (HIMS) Rises But Trails Market: What Investors Should Know

In the closing of the recent trading day, Hims & Hers Health, Inc. (HIMS) stood at $14.60, denoting a +0.34% change from the preceding trading day.

What Makes Hims & Hers Health, Inc. (HIMS) a Strong Momentum Stock: Buy Now?

Does Hims & Hers Health, Inc. (HIMS) have what it takes to be a top stock pick for momentum investors? Let's find out.

Why Hims & Hers Health, Inc. (HIMS) Might be Well Poised for a Surge

Hims & Hers Health, Inc. (HIMS) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Lilly (LLY) Starts Website to Help Access Tirzepatide Drugs

Eli Lilly's (LLY) digital pharmacy is expected to provide patients easy access to its FDA-approved tirzepatide medicines, Mounjaro and Zepbound.

Hims & Hers Health, Inc. (HIMS) Moves 8.3% Higher: Will This Strength Last?

Hims & Hers Health, Inc. (HIMS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Wall Street Analysts Predict a 70.23% Upside in Hims & Hers Health, Inc. (HIMS): Here's What You Should Know

The consensus price target hints at a 70.2% upside potential for Hims & Hers Health, Inc. (HIMS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.